145 related articles for article (PubMed ID: 36962423)
1. Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study.
Seaman CP; Mvundura M; Frivold C; Morgan C; Jarrahian C; Howell J; Hellard M; Scott N
PLOS Glob Public Health; 2022; 2(5):e0000394. PubMed ID: 36962423
[TBL] [Abstract][Full Text] [Related]
2. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study.
Seaman CP; Morgan C; Howell J; Xiao Y; Spearman CW; Sonderup M; Lesi O; Andersson MI; Hellard ME; Scott N
Lancet Glob Health; 2020 Jul; 8(7):e931-e941. PubMed ID: 32562649
[TBL] [Abstract][Full Text] [Related]
3. Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.
Fu H; Abbas K; Malvolti S; Gregory C; Ko M; Amorij JP; Jit M
BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37949503
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
Scott N; Palmer A; Morgan C; Lesi O; Spearman CW; Sonderup M; Hellard M
Lancet Glob Health; 2018 Jun; 6(6):e659-e667. PubMed ID: 29773122
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study).
Gosset A; Diallo MY; Betsem E; Schaeffer L; Meda N; Vray M; Sombie R; Shimakawa Y; Boyer S
Vaccine; 2021 Jul; 39(33):4659-4670. PubMed ID: 34238606
[TBL] [Abstract][Full Text] [Related]
7. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
Li X; Mukandavire C; Cucunubá ZM; Echeverria Londono S; Abbas K; Clapham HE; Jit M; Johnson HL; Papadopoulos T; Vynnycky E; Brisson M; Carter ED; Clark A; de Villiers MJ; Eilertson K; Ferrari MJ; Gamkrelidze I; Gaythorpe KAM; Grassly NC; Hallett TB; Hinsley W; Jackson ML; Jean K; Karachaliou A; Klepac P; Lessler J; Li X; Moore SM; Nayagam S; Nguyen DM; Razavi H; Razavi-Shearer D; Resch S; Sanderson C; Sweet S; Sy S; Tam Y; Tanvir H; Tran QM; Trotter CL; Truelove S; van Zandvoort K; Verguet S; Walker N; Winter A; Woodruff K; Ferguson NM; Garske T;
Lancet; 2021 Jan; 397(10272):398-408. PubMed ID: 33516338
[TBL] [Abstract][Full Text] [Related]
8. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
9. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
10. Modelling the Cost-Effectiveness of Hepatitis A in South Africa.
Patterson J; Cleary S; Norman JM; Van Zyl H; Awine T; Mayet S; Kagina B; Muloiwa R; Hussey G; Silal SP
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400100
[TBL] [Abstract][Full Text] [Related]
11. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
12. Mathematical models of cervical cancer prevention in Latin America and the Caribbean.
Goldie SJ; Diaz M; Constenla D; Alvis N; Andrus JK; Kim SY
Vaccine; 2008 Aug; 26 Suppl 11():L59-72. PubMed ID: 18945403
[TBL] [Abstract][Full Text] [Related]
13. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
15. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique.
Klingler C; Thoumi AI; Mrithinjayam VS
Vaccine; 2012 Dec; 31(1):252-9. PubMed ID: 22902676
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
